Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

By Jeffrey S. Miller, Y. Soignier, A. Panoskaltsis‐Mortari, S. McNearney, Gong H Yun, S. Fautsch, D. McKenna, C. Le, T. Defor, L. Burns and 7 more. Blood, 2005

1,841 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/50739b588d10bdd332a4e986240cfe694e90efce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Blaise
2. É. Vivier
3. G. Lal
4. Christian Chabannon
5. S. Ugolini
6. T. Walzer
7. K. Rezvani
8. S. Paul

Citations in the corpus

• Pre-activation with IL-12, IL-15, and IL-18 induces CD25 and a functional high affinity IL-2 receptor on human cytokine-induced memory-like NK cells (2014, background): “What are the clinical implications of peripheral blood NK cell acquisition of a functional high-affinity IL-2Rabg? Allogeneic NK cell therapy has evidence of antileukemic activity in clinical trials in acute myelogenous leukemia patients [46].”
• The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy (2017, background): “Adoptive transfer of haploidentical NK cells from KIR-mismatched donor has been shown to be safe and also mediate complete remission in AML patients (143, 144).”
• Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells (2012, methodology): “Using this approach, Miller et al [14] demonstrated that infusion of haploidentical NK cells after chemotherapy could induce remission in poor-prognosis AML patients, and remission was associated with KIR mismatch.”
• CAR-NK cells: A promising cellular immunotherapy for cancer (2020, background): “[34] In addition to reducing NK cell rejection by the recipient, lymphodepleting chemotherapy might reprogram an immunosuppressive host TME by depleting myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), and thus create a cytokine milieu that favours NK cell expansion after inf”
• Functions of natural killer cells (2008, background): “, and NK cell–mediated therapy after hematopoietic cell transplantation seems saf”
• Targeting natural killer cells and natural killer T cells in cancer (2012, background): “Injections of mature HLA-mismatched NK cells are also well tolerate”
• Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity (2017, positive): “Functional NK cells can be derived from several sources.(9, 12, 13) Autologous NK cells can be reproducibly generated in vitro, but have limited activity against autologous tumors, (14, 15) which may not be overcome by CAR engineering.”